Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced preliminary results of a Phase 1 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary results as of April 2009 showed that OGX-427 was well tolerated as a monotherapy. In addition, OGX-427 demonstrated declines in circulating tumor cells at all doses evaluated as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells and tumor markers both suggest single-agent activity warranting further clinical investigation.

The Phase 1 trial has evaluated 41 patients with a variety of cancers to date; enrollment is ongoing. The first phase of the study evaluated increasing doses of OGX-427 as a single agent up to 1000 mg. A maximum tolerated dose was not identified up to and including the 1000-mg dose of OGX-427 monotherapy. Subsequently, as defined by the protocol, an 800-mg dose of OGX-427 in combination with docetaxel was evaluated, to be followed by a 1000-mg dose of OGX-427 plus docetaxel. OGX-427 is administered as three loading doses within the first 9 days and then continued weekly, with three weeks defined as a treatment cycle, until disease progression or toxicity. In those groups receiving OGX-427 in combination with docetaxel, 75mg/M(2) docetaxel was administered on Day 1 of every 3-week cycle starting after completion of the OGX-427 loading doses.

Safety Results

Patients enrolled had a diagnosis of breast, ovarian, prostate or non-small cell lung cancer and most had failed multiple prior chemotherapy treatments. A median of 2 cycles (range of 1-8 cycles) was administered with the following safety results for OGX-427 as monotherapy:

    -   Criteria for a maximum tolerated dose were 
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Jersey (PRWEB) September 30, 2014 ... has been chosen by the Parenteral Drug Association ... 18 and 19, 2014) on container closure integrity testing. ... closure integrity test methods and philosophies detailed in the ... Integrity Evaluation. The course will span container ...
(Date:9/29/2014)... start of the military conflicts in Iraq and Afghanistan, ... States with traumatic brain injury caused by exposure to ... explosive devices, or IEDs. Symptoms of traumatic brain injury ... and nausea, to more severe impairments in memory and ... Defense has recognized the critical importance and complexity of ...
(Date:9/29/2014)... Present-day lithium batteries are efficient but involve a ... from alfalfa (lucerne seed) and pine resin and ... come up with a highly interesting alternative. Their ... journal ChemSusChem . , ,We think our ... energy-efficient solutions for the batteries of the future, ...
(Date:9/29/2014)... Mass. , Sept. 29, 2014  Atlas Venture, ... life sciences and technology innovation, today announced that ... Epizyme (NASDAQ: EPZM ), is joining the ... October 1, 2014. At Atlas, Rhodes will ... groundbreaking companies. He brings an accomplished record in company ...
Breaking Biology Technology:Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4Smart, eco-friendly new battery to solve problems 2Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team 2
... Software, a leading provider of image data management tools for ... Open Microscopy Environment Consortium, is proud that its founder Professor ... this year,s BBSRC Innovator of the Year. The BBSRC is ... in the non-clinical life sciences, and along with the Wellcome ...
... the best education and to absorb what they are ... the journal Academic Medicine * connects research on how ... real world education, particularly the education of doctors. "Repetition, ... knowing what is happening in the brain will enhance teaching ...
... surgeon Dr. Lewis Groden presented results from a ... and Refractive Surgery (ASCRS) Symposium revealing that LASIK procedures ... and very high patient satisfaction rates. Each ... vision center currently offers patients a choice of multiple ...
Cached Biology Technology:Glencoe Software and Open Microscopy Environment Founder Awarded the BBSRC Innovator of the Year 2011 2Brain scientists offer medical educators tips on the neurobiology of learning 2Brain scientists offer medical educators tips on the neurobiology of learning 3Brain scientists offer medical educators tips on the neurobiology of learning 4Brain scientists offer medical educators tips on the neurobiology of learning 5LasikPlus® Research Reveals Excellent Results From Modern LASIK 2
(Date:9/29/2014)... Joint Genome Institute (DOE JGI), a DOE Office ... new projects have been selected for the 2015 ... to Caribbean waters, and from plant root micro-ecosystems, ... forested watersheds, the CSP 2015 projects portfolio highlights ... extracted. , "These projects catalyze JGI,s strategic ...
(Date:9/29/2014)... can DNA from the skeleton of a man who lived ... us about ourselves as humans? A great deal when his ... in genetic terms found to-date in a region where ... ago. , The man,s maternal DNA, or ,mitochondrial DNA, ... and evolution. Mitochondrial DNA provided the first evidence that we ...
(Date:9/29/2014)... CHAMPAIGN, Ill. Scientists have discovered a previously ... divide, grow and, in the case of estrogen-positive ... the work reveals new targets for breast cancer ... need the most aggressive treatment. , The University ... journal Oncogene . , Estrogen pre-activates the ...
Breaking Biology News(10 mins):2015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9Ancient human genome from southern Africa throws light on our origins 2Ancient human genome from southern Africa throws light on our origins 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... researchers have found that the naturally occurring marine toxin ... in rats exposed to the chemical before birth. Humans ... after eating contaminated shellfish. , The researchers saw ... exposure to domoic acid levels below those generally deemed ...
... (Nasdaq: SLXA) today announced that its researchers in collaboration ... Delaware reported the most comprehensive analysis to date of ... "Elucidation of the Small RNA Component of the Transcriptome," ... the peer-reviewed journal Science. Solexa's assay can be used ...
... Medicine uses PET, radiotracer to track enzyme in smokers, ... in the lungs, possibly contributing to some of smoking's ... the September issue of the Journal of Nuclear Medicine. ... enzyme, also shows that smokers had a lower concentration ...
Cached Biology News:Prenatal exposure to marine toxin causes lasting damage 2Prenatal exposure to marine toxin causes lasting damage 3Solexa and collaborating scientists illuminate the small RNA component of the transcriptome 2Smoking damages key regulatory enzyme in the lung 2Smoking damages key regulatory enzyme in the lung 3
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
...
Form: Concentrated Applications: ELISA...
Form: Ready to use Applications: ELISA...
Biology Products: